Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Reed F Beall

Showing results (1-10 of 62) with videos related to

Pageof 7
Sort By:
Social Science & Medicine (1982)|June 5, 2017
A method for understanding generic procurement of HIV medicines by developing countries with patent protectionReed F Beall, Amir Attaran
Nature Biotechnology|September 9, 2016
Which patent and where? Why international patent transparency by companies is needed for medicinesReed F Beall, Amir Attaran
Nature Medicine|August 8, 2012
The time for pharmaceutical compulsory licensing has expiredRandall Kuhn, Reed F Beall
Drug Discovery Today|August 11, 2020
Global clinical trial mobilization for COVID-19: higher, faster, strongerReed F Beall, Aidan Hollis
Journal of Pharmaceutical Policy and Practice|July 23, 2016
The global intellectual property ecosystem for insulin and its public health implications: an observational studyWarren A Kaplan, Reed F Beall
Nature Biotechnology|February 7, 2018
Tertiary patenting on drug-device combination products in the United StatesReed F Beall, Aaron S Kesselheim
Healthcare Policy = Politiques De Sante|June 16, 2020
Commentary: Expedited Regulatory Review of Low-Value DrugsJonathan J Darrow, Reed F Beall
Globalization and Health|June 28, 2017
In which developing countries are patents on essential medicines being filed?Reed F Beall, Rosanne Blanchet, Amir Attaran
Health Affairs (Project Hope)|March 4, 2015
Compulsory licensing often did not produce lower prices for antiretrovirals compared to international procurementReed F Beall, Randall Kuhn, Amir Attaran
Health Affairs (Project Hope)|June 10, 2015
Compulsory Licenses: The Authors ReplyReed F Beall, Amir Attaran, Randall Kuhn
Pageof 7

Showing results (1-10 of 62) with videos related to

Sort By:
Pageof 7
Social Science & Medicine (1982)|June 5, 2017
A method for understanding generic procurement of HIV medicines by developing countries with patent protectionReed F Beall, Amir Attaran
Nature Biotechnology|September 9, 2016
Which patent and where? Why international patent transparency by companies is needed for medicinesReed F Beall, Amir Attaran
Nature Medicine|August 8, 2012
The time for pharmaceutical compulsory licensing has expiredRandall Kuhn, Reed F Beall
Drug Discovery Today|August 11, 2020
Global clinical trial mobilization for COVID-19: higher, faster, strongerReed F Beall, Aidan Hollis
Journal of Pharmaceutical Policy and Practice|July 23, 2016
The global intellectual property ecosystem for insulin and its public health implications: an observational studyWarren A Kaplan, Reed F Beall
Nature Biotechnology|February 7, 2018
Tertiary patenting on drug-device combination products in the United StatesReed F Beall, Aaron S Kesselheim
Healthcare Policy = Politiques De Sante|June 16, 2020
Commentary: Expedited Regulatory Review of Low-Value DrugsJonathan J Darrow, Reed F Beall
Globalization and Health|June 28, 2017
In which developing countries are patents on essential medicines being filed?Reed F Beall, Rosanne Blanchet, Amir Attaran
Health Affairs (Project Hope)|March 4, 2015
Compulsory licensing often did not produce lower prices for antiretrovirals compared to international procurementReed F Beall, Randall Kuhn, Amir Attaran
Health Affairs (Project Hope)|June 10, 2015
Compulsory Licenses: The Authors ReplyReed F Beall, Amir Attaran, Randall Kuhn
Pageof 7